ANIK Q4 2024 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q4 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

-$1M-103.0% YoY

Gross Profit

$23M-1749.2% margin

Operating Income

$28M-2156.4% margin

Net Income

-$22M1695.0% margin

EPS (Diluted)

$-1.50

QoQ Revenue Growth

-103.3%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$275,000

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$203M

Total Liabilities

$49M

Stockholders' Equity

$154M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$1M	$43M	-103.0%
Gross Profit	$23M	$26M	-14.3%
Operating Income	$28M	-$64M	+143.6%
Net Income	-$22M	-$63M	+65.3%

Geographic Segments

UNITED STATES

$26M77%

Europe

$8M23%